▎WuXiEdited by Kant Content Team

Pearl Bio today announced that it has signed an agreement with MSD worth up to$1 billionLicense, collaboration, and option agreement to jointly discover and develop biologics therapies containing non-standard amino acids for cancer through its proprietary GRO (Genomically Recoded Organisms) platform.

The company's GRO platform is primarily built on the research of its scientific co-founders, Dr. Farren Isaacs from Yale University and Dr. Michael Jewett from Stanford University.The platform can be used to encode and synthesize new chemicals, and develop multifunctional biologics with tunable properties.

The collaboration will initially focus on leveraging Pearl Bio's proprietary GRO technology, which offers unique capabilities usable in both cellular and cell-free systems, and targets previously difficult-to-target epitopes, to discover and develop biologics therapies for cancer treatment.

Image Source: 123RF

According to the agreement,Pearl Bio is eligible to receive total upfront and milestone payments of up to 1 billion US dollars.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.